上海复宏汉霖生物技术股份有限公司 Henlius
{{company.company_channel.channel_name}}
Media Room
{{company.company_name_local}}
{{company.company_channel.channel_name}}
Company Profile
Media Room
Henlius Forecasts Profit in 1H 2023 2023-07-03 17:49
Henlius Achieved Steep Revenue Growth in Q1 2023, Core Products Sales Surged 2023-04-17 07:45
Henlius 2022 Annual Results: Significant Achievements in Commercialisation, Surged to RMB3.2 Billion in Revenues 2023-04-01 00:06
EMA Validates Marketing Authorization Application for Henlius' HANSIZHUANG (Serplulimab) 2023-03-24 08:00
Henlius Announces U.S. FDA Acceptance of Biologics License Application for Proposed Biosimilar Trastuzumab HLX02 2023-02-15 16:49
Henlius' Novel Anti-PD-1 mAb HANSIZHUANG (Serplulimab) Approved for the Treatment of ES-SCLC 2023-01-17 19:42
First Patient dosed in a Head-to-Head First-Line Bridging Study of HANSIZHUANG for ES-SCLC treatment in the US 2022-11-30 08:00
Henlius' Novel Anti-PD-1 mAb HANSIZHUANG (Serplulimab) Receives NMPA Approval for the Treatment of sqNSCLC 2022-11-01 21:32
ASTRUM-005: The first immunotherapy clinical study of SCLC published in JAMA, one of the top medical journals in the world 2022-09-28 21:00
Henlius 2022 H1 Results: Sharpen all-round edges, advance in evolution to Biopharma 2022-08-18 21:35
Henlius HANQUYOU Received TGA Approval in Australia 2022-07-26 18:03
Palleon Pharmaceuticals and Henlius Enter into Strategic Collaboration to Develop Bifunctional Sialidase Therapies 2022-06-28 21:50
ASTRUM-005: Henlius Released Phase 3 Study Results for the First-line Treatment of Small Cell Lung Cancer of Serplulimab at ASCO 2022 2022-06-06 21:00
The NDA of Henlius Novel Anti-PD-1 mAb Serplulimab for the First-Line Treatment of Small Cell Lung Cancer Accepted by NMPA 2022-04-11 22:07
Henlius' Serplulimab Granted Orphan-Drug Designation in the United States for Small Cell Lung Cancer 2022-04-07 22:21
Henlius Receives NMPA Approval for its First Innovative Monoclonal Antibody HANSIZHUANG 2022-03-25 21:24
Henlius 2021 Annual Results: New Record in Performance, Evolving to Biopharma 2022-03-17 08:00
Henlius 2021 Annual Results: New Record in Performance, Evolving to Biopharma 2022-03-16 23:46
Henlius' anti-PD-1 mAb MRCT achieved 15.38 months OS in first-line treatment of SCLC, reducing the risk of death by 38% of the overall population 2021-12-20 22:00
Henlius' Phase 3 clinical study of novel PD-1 inhibitor serplulimab for the treatment of first-line extensive-stage small cell lung cancer (ES-SCLC) meets primary study endpoint 2021-12-08 08:30
1 2 3